IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 11.05 SEK -0.45%
Market Cap: 572.3m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

Relative Value

The Relative Value of one IRLAB A stock under the Base Case scenario is 17.86 SEK. Compared to the current market price of 11.05 SEK, IRLAB Therapeutics AB is Undervalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IRLAB A Relative Value
Base Case
17.86 SEK
Undervaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
39
vs Industry
9
Median 3Y
12.3
Median 5Y
11
Industry
2.5
Forward
4.6
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-4
Industry
21.8
Forward
-6.5
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-7.4
Industry
16.1
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-12.3
Industry
23.8
vs History
1
vs Industry
6
Median 3Y
5.3
Median 5Y
5.7
Industry
2.1
vs History
38
vs Industry
9
Median 3Y
10.1
Median 5Y
8
Industry
2.7
Forward
3.9
vs History
vs Industry
Median 3Y
-4
Median 5Y
0
Industry
5.2
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.6
Industry
13.5
Forward
-7.1
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.6
Industry
16.8
Forward
-6.8
vs History
vs Industry
Median 3Y
-2
Median 5Y
-6.2
Industry
15.2
vs History
vs Industry
Median 3Y
-2
Median 5Y
-6.2
Industry
19.3
vs History
69
vs Industry
15
Median 3Y
9.2
Median 5Y
13.6
Industry
1.9

Multiples Across Competitors

IRLAB A Competitors Multiples
IRLAB Therapeutics AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
IRLAB Therapeutics AB
STO:IRLAB A
573.1m SEK 10 -2.2 -1.9 -1.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 18.5 90.3 48.5 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
SE
IRLAB Therapeutics AB
STO:IRLAB A
Average P/S: 382 942.9
10
1 499%
0
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
SE
IRLAB Therapeutics AB
STO:IRLAB A
Average P/E: 32.4
Negative Multiple: -2.2
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
IRLAB Therapeutics AB
STO:IRLAB A
Average EV/EBITDA: 459.6
Negative Multiple: -1.9
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
IRLAB Therapeutics AB
STO:IRLAB A
Average EV/EBIT: 2 011.3
Negative Multiple: -1.9
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top